{
    "clinical_study": {
        "@rank": "109442", 
        "acronym": "PUSH-PATH-2", 
        "arm_group": [
            {
                "arm_group_label": "Prednisone", 
                "arm_group_type": "Experimental", 
                "description": "Prednisone will be given 30mg/day for 2 weeks and then tapered off."
            }, 
            {
                "arm_group_label": "Allopurinol", 
                "arm_group_type": "Active Comparator", 
                "description": "Allopurinol will be given 100 mg/day initially, and then titrated to 200 mg/day."
            }
        ], 
        "brief_summary": {
            "textblock": "Hyperuricemia is a very common finding in patients with heart failure. It is usually related\n      to diuretic use and deteriorated renal function. The recently evidence showed that\n      prednisone and allopurinol may have similar effect on uric acid (UA) lowering in symptomatic\n      heart failure patients with hyperuricemia, but prednisone may be superior over allopurinol\n      in renal function improvement. Thus the investigators design this randomized head to head\n      study to test their hypothesis that prednisone is superior over allopurinol in renal\n      function improvement despite their similar effect on UA lowering in heart failure patients\n      with hyperuricemia."
        }, 
        "brief_title": "Prednisone for Heart Failure Patients With Hyperuricemia", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Heart Failure, Hyperuricemia", 
        "condition_browse": {
            "mesh_term": [
                "Heart Failure", 
                "Hyperuricemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  chronic congestive heart failure\n\n          -  18-80 years old\n\n          -  NYHA Class II-IV\n\n          -  Serum uric acid > 7mg/dl\n\n          -  left ventricular ejection fraction \u2264 45%\n\n        Exclusion Criteria:\n\n          -  Acute gouty arthritis;\n\n          -  Any condition (other than heart failure) that could limit the use of prednisone or\n             xanthine oxidase inhibitors;\n\n          -  Acute decompensated heart failure;\n\n          -  Any concurrent disease that likely limits life expectancy;\n\n          -  Active myocarditis, or an hypertrophic obstructive or restrictive cardiomyopathy;\n\n          -  Myocardial infarction, stroke, unstable angina, or cardiac surgery within the\n             previous 3 months;\n\n          -  Indication for hemodialysis\n\n          -  Creatinine> 3.0 mg per deciliter at admission to the hospital\n\n          -  Uncontrolled systolic blood pressure > 160 mmHg\n\n          -  Known bilateral renal artery stenosis\n\n          -  Complex congenital heart disease\n\n          -  Any signs of infections\n\n          -  Enrollment in another clinical trial involving medical or device-based interventions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02129764", 
            "org_study_id": "PUSH-PATH 2"
        }, 
        "intervention": [
            {
                "arm_group_label": "Prednisone", 
                "intervention_name": "Prednisone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Allopurinol", 
                "intervention_name": "Allopurinol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Allopurinol", 
                "Prednisone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 30, 2014", 
        "location": {
            "contact": {
                "email": "ksliud@sohu.com", 
                "last_name": "Kunshen Liu", 
                "phone": "8631185917033"
            }, 
            "facility": {
                "address": {
                    "city": "Shijiazhuang", 
                    "country": "China", 
                    "state": "Hebei", 
                    "zip": "050031"
                }
            }, 
            "investigator": {
                "last_name": "Kuns Liu, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Prednisone in Uric Acid Lowering in Symptomatic Heart Failure PATients With Hyperuricemia (PUSH-PATH Study 2)", 
        "overall_contact": {
            "email": "ksliud@sohu.com", 
            "last_name": "Kunshen Liu", 
            "phone": "8631185917033"
        }, 
        "overall_contact_backup": {
            "email": "dr.liuchao@gmail.com", 
            "last_name": "Chao Liu", 
            "phone": "8631185917032"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Health Bureau of Hebei Province", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change form baseline in serum creatinine levels", 
            "safety_issue": "Yes", 
            "time_frame": "2 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02129764"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hebei Medical University", 
            "investigator_full_name": "Kun-shen Liu M.D.", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in uric acid levels", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "measure": "Change from baseline in Cystatin C", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "measure": "the levels of tumor necrosis factor (TNF) alfa, interleukin (IL)-1 beta and IL-6 in the circulation", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "measure": "The levels of angiotensin II and aldosterone in the circulation.", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "measure": "Daily urine output", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "measure": "New York Heart Association (NYHA) functional class", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }
        ], 
        "source": "Hebei Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hebei Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}